(Total Views: 8790)
Posted On: 03/31/2024 1:16:13 AM
Post# of 156315
Feb. 2023 Cytodyn patent:
" The present invention relates to competitive inhibitors to the CCR5 receptor and the use of such competitive inhibitors, such as monoclonal antibodies (including, but not limited to, PRO 140), fragments or subunits of same, proteins, small molecules, or conjugates of any of the above, of the CCL5 ligand/CCR5 receptor axis that express antagonist activity for RANTES (CCL5), MIP1-alpha (CCL3), and MIP1-beta (CCL4) in the fields of transplantation, including graft versus host disease (GvHD), autoimmune disorders (Multiple Sclerosis (MS), Lupus, psoriasis, liver disease, Crohn's Disease, Inflammatory bowel disease, etc.), infectious agents, chronic inflammation, and cancer, including, but not limited to, breast cancer, prostate cancer, etc. The competitive inhibitors of the present invention may be used to inhibit, interrupt, block, mitigate, dampen, slow the progress of, and/or treat inflammation or various other CCR5/CCL5 axis signaling dependent down-stream activities associated with GvHD, autoimmune disorders, infectious agents, chronic inflammation, and cancer."
https://patents.justia.com/patent/11584797
Dosen't this cover the current immunmodulating of chronic inflammation protocol & etc., etc.. mentioned by Dr. J & the medical shareholders outstanding posts ??
Sorry if this patent's already been mentioned here in the past...
" The present invention relates to competitive inhibitors to the CCR5 receptor and the use of such competitive inhibitors, such as monoclonal antibodies (including, but not limited to, PRO 140), fragments or subunits of same, proteins, small molecules, or conjugates of any of the above, of the CCL5 ligand/CCR5 receptor axis that express antagonist activity for RANTES (CCL5), MIP1-alpha (CCL3), and MIP1-beta (CCL4) in the fields of transplantation, including graft versus host disease (GvHD), autoimmune disorders (Multiple Sclerosis (MS), Lupus, psoriasis, liver disease, Crohn's Disease, Inflammatory bowel disease, etc.), infectious agents, chronic inflammation, and cancer, including, but not limited to, breast cancer, prostate cancer, etc. The competitive inhibitors of the present invention may be used to inhibit, interrupt, block, mitigate, dampen, slow the progress of, and/or treat inflammation or various other CCR5/CCL5 axis signaling dependent down-stream activities associated with GvHD, autoimmune disorders, infectious agents, chronic inflammation, and cancer."
https://patents.justia.com/patent/11584797
Dosen't this cover the current immunmodulating of chronic inflammation protocol & etc., etc.. mentioned by Dr. J & the medical shareholders outstanding posts ??
Sorry if this patent's already been mentioned here in the past...
(9)
(0)
